Retatrutide (30mg) vial
Currently unavailable

Retatrutide

30mg Lyophilised Powder

$329.99AUD per vial

Concentration

30mg

CAS Number

2381089-83-2

Volume Savings

1
Express shipping available Australia-wide
Independently laboratory tested with CoA available

Currently unavailable

Purity as reported on CoA: 99.882%

Frequently Bought Together

Retatrutide (10mg)

Support

Retatrutide (10mg)

$139.99

BPC-157 (10mg)

Support

BPC-157 (10mg)

$89.99

GLOW Peptide Blend (50mg)

Support

GLOW Peptide Blend (50mg)

$168.99

Product Information

Retatrutide 30mg Research Peptide – High-Volume Compound for Extended Laboratory Use

Retatrutide (30mg) from Aus Peptide Supply is a high-purity research peptide produced for controlled laboratory and in-vitro research applications where extended compound availability is required. Manufactured under strict quality standards, this triple GLP-1/GIP/Glucagon receptor agonist is supplied for scientific investigation and analytical purposes only.

Product Highlights

  • High Purity Standard – Produced using advanced synthesis and purification processes, batch-verified at 99.882% purity as reported on the CoA.
  • Research-Grade Quality Control – Subjected to rigorous third-party analytical testing for identity and purity verification via HPLC and mass spectrometry.
  • Secure Packaging – Delivered in sterile, sealed vials to safeguard compound stability during transport and storage.
  • Reliable Domestic Sourcing – Dispatched from within Australia in compliance with established laboratory handling and quality assurance protocols.

Intended Use

Retatrutide (30mg) is intended exclusively for laboratory research and scientific study. It is not intended for human or veterinary use, therapeutic application, or consumption. Researchers are responsible for ensuring proper handling, storage, and application in accordance with applicable regulations and institutional guidelines.

Storage & Handling

  • Store in a cool, dry environment away from direct light. Lyophilised vials should be kept at -20°C.
  • Reconstitute using appropriate laboratory-grade solvents (such as bacteriostatic water) where applicable.
  • Follow standard laboratory safety procedures when handling peptide compounds.

For research environments requiring a single high-volume vial to support long-duration experimental protocols, Retatrutide (30mg) delivers the same verified purity and batch consistency as smaller formats without the need for mid-protocol reordering. Fast domestic shipping to all Australian states and territories, with batch-specific CoA information available in our CoA Library.

⚠ For in-vitro research and laboratory use only. Not for human consumption.

Frequently Asked Questions

What is Retatrutide?
Retatrutide is a synthetic peptide that acts as a triple agonist at the GLP-1, GIP, and glucagon receptors simultaneously. This tri-receptor activity is what separates it from earlier compounds like semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP), and is the basis for the significant fat loss results observed in Phase 2 clinical trials — including a mean body weight reduction of up to 24% over 48 weeks.
Why choose the 30mg vial?
The 30mg vial covers a full extended protocol in one purchase. At a typical 2mg weekly application, 30mg gives you roughly 15 weeks — about three and a half months — without reordering or swapping batches. It's the sweet spot between the 10mg starter and the bulk 60mg format: enough for a complete serious protocol, at a better price per milligram than the 10mg, without the larger upfront outlay of the 60mg.
How does Retatrutide compare to semaglutide and tirzepatide?
Semaglutide (Ozempic/Wegovy) targets one receptor — GLP-1. Tirzepatide (Mounjaro) targets two — GLP-1 and GIP. Retatrutide targets three — GLP-1, GIP, and glucagon. In Phase 2 trials, Retatrutide produced a mean 24% body weight reduction over 48 weeks. Tirzepatide achieved around 20% in comparable studies, semaglutide around 14–15%. The glucagon receptor component — which directly increases energy expenditure — is what Retatrutide has and the others don't.
What is Retatrutide also known as?
In the research community, Retatrutide is commonly referred to as Reta peptide or simply Reta. It is also sometimes searched for as Reda peptide or Retatrude — both common misspellings. The shorthand r3ta peptide (using a numeral 3) also appears frequently in online research communities. One particularly common autocorrect error is 'ratatouille peptide' — if that's what brought you here, you're in the right place.
Can Australian compounding pharmacies supply Retatrutide now, and when will it be released commercially?
Retatrutide is still an investigational compound, not an approved commercial medicine currently available to the public in Australia. Aus Peptide Supply does not supply Retatrutide as a compounded prescription product or pharmacy medicine — we supply research-grade lyophilised powder for lawful in-vitro laboratory research only. Lilly states that Retatrutide is not yet available for public use, remains in Phase 3 clinical trials, and that public launch depends on the completion of those trials plus regulatory approval, with additional Phase 3 results anticipated in 2026.
How does Retatrutide work?
Retatrutide hits three separate pathways at once: GLP-1 receptors suppress appetite and slow digestion; GIP receptors improve insulin sensitivity and amplify fat loss; glucagon receptors increase energy expenditure by driving the liver to burn more fuel. Most weight loss compounds only target one or two of these — Retatrutide targets all three simultaneously, which is why the Phase 2 results were so far ahead of anything that came before it.
What does the research show about Retatrutide?
Phase 2 clinical trials observed mean body weight reductions of up to 24% over 48 weeks — significantly outperforming semaglutide and tirzepatide in head-to-head comparisons. Subjects showed dramatic reductions in waist circumference, visceral fat, and improvements across key cardiometabolic markers including blood pressure and LDL cholesterol. The appetite suppression was described as profound, with energy intake reductions sustained throughout the full trial period.
How do you reconstitute Retatrutide (30mg)?
Retatrutide is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use. Inject the BAC water slowly into the vial, directing the stream down the inside wall. Gently swirl to dissolve — do not shake. Once reconstituted, store at 2–8°C and use within 28 days. For a full step-by-step walkthrough, see our complete peptide reconstitution guide.
How should Retatrutide (30mg) be stored?
Store lyophilized Retatrutide (30mg) vials at -20°C, away from light and moisture. After reconstitution with BAC water, refrigerate at 2–8°C and use within 28 days. Do not freeze the reconstituted solution.
Where to buy Retatrutide 30mg in Australia?
Retatrutide (30mg) is available through Aus Peptide Supply with fast domestic shipping to all Australian states and territories. Every vial is dispatched from within Australia — no customs delays, no international freight uncertainty. Each batch undergoes third-party analysis and the Certificate of Analysis is available to view in our CoA library.
What is the cost of Retatrutide 30mg in Australia?
Retatrutide (30mg) is priced at $329.99 per vial, which works out to approximately $11.00 per milligram at Aus Peptide Supply.

Purchase Other Quantities

Retatrutide is also available in other vial sizes. Compare the current formats below and jump straight to the quantity that fits your protocol.

Retatrutide (10mg)

PEP-007-10MG

$139.99

Available to purchase now

View this quantity →

Retatrutide (20mg)

PEP-024-20MG

$229.99

Currently unavailable

View this quantity →

Retatrutide (30mg)

PEP-019-30MG

Current

$329.99

Currently unavailable

Viewing this quantity →

Retatrutide (60mg)

PEP-025-60MG

$549.99

Currently unavailable

View this quantity →